A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer (Q34363435)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

based on heuristic

inferred from title

author name string

I M E Desar

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

J N H Timmer-Bonte

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

D M Burger

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

W T A van der Graaf

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

C M L van Herpen

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

2 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

103

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1637-1643

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Combination targeted therapy in advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Targeting the mTOR signaling network for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2994217

6 July 2018

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605777

21 January 2018

Identifiers

10.1038/SJ.BJC.6605777

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34363435&oldid=2196551286"